MBX Biosciences, Inc. Common Stock
NASDAQ:MBXBiotechnology
-$0.64 today
- Market cap
- $2.65B
- Beta
- 0.75
- P/E (TTM)
- -22.0
- EPS (TTM)
- -$1.86
Volume 0.73M
Average 0.65M
MBX Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
MBX Biosciences, Inc. Common StockNASDAQ: MBX
Cash & Equivalents · Q3 FY2026 · quarter ended Sep 2026
Cash & equivalents falls 27.5% from a year ago
Cash & equivalents stood at $161.69M at the end of Q3 FY2026, down 27.5% from a year earlier and up 198.7% from the prior quarter. Over 3 fiscal years it compounded at +46.0% a year.
Context
- Cash & equivalents amounted to 32.3% of total assets at the end of Q3 FY2026, down 23.5 pp from a year earlier.
- Cash & equivalents increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -27.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 75.29M USD
- Year-over-year change
- +52.6%
- 3-year CAGR
- +46.0%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 75.29M | +52.6% |
| FY2024 | 2024-12-31 | 49.35M | +61.7% |
| FY2023 | 2023-12-31 | 30.52M | +26.1% |
| FY2022 | 2022-12-31 | 24.21M | — |
Cash & Equivalents vs competitors
How MBX compares with its peers on the latest reported figures
- Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -27.5% is the 7th highest of 8, against a peer median of +78.9%.
- Cash & equivalents amounts to 32.3% of total assets for MBX, versus a peer median of 26.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | €964.36M EUR | +78.9% | +11.5% | 39.7% | |
MBXMBX Biosciences, Inc. Common Stock | Sep 2026 | $161.69M USD | -27.5% | +46.0% | 32.3% |
KLRAKailera Therapeutics, Inc. | Jun 2026 | $130.3M USD | — | — | 10.8% |
| Jun 2026 | $125.75M USD | +271.2% | +65.4% | 24.1% | |
| Mar 2026 | $111.75M USD | +91.2% | -3.1% | 28.5% | |
| Mar 2026 | $97.6M USD | +98.8% | -26.7% | 29.1% | |
| Mar 2026 | $44.69M USD | +24.6% | -20.7% | 96.4% | |
| Sep 2026 | $39.98M USD | -23.2% | -24.8% | 9.0% | |
| Mar 2026 | $13.2M USD | -82.3% | +4.3% | 4.9% | |
| Peer median (excluding MBX) | — | +78.9% | -3.1% | 26.3% | |
Competitors are the stored peer set for MBX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX
Intrinsic Alpha fair value
Locked
Current Price
$53.42
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.